Arvinas Stock Price, News & Analysis (NASDAQ:ARVN)

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

13 Wall Street research analysts have issued 12 month target prices for Arvinas' shares. Their ARVN share price targets range from $20.00 to $95.00. On average, they anticipate the company's stock price to reach $51.77 in the next twelve months. This suggests a possible upside of 135.6% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN shares have decreased by 35.8% and is now trading at $21.97.
View the best growth stocks for 2023 here.

Arvinas saw a decrease in short interest in November. As of November 15th, there was short interest totaling 2,140,000 shares, a decrease of 18.0% from the October 31st total of 2,610,000 shares. Based on an average trading volume of 491,800 shares, the days-to-cover ratio is presently 4.4 days. Approximately 4.5% of the company's shares are sold short.
View Arvinas' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) posted its earnings results on Tuesday, November, 7th. The company reported ($1.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.58) by $0.40. The firm had revenue of $34.60 million for the quarter, compared to analysts' expectations of $39.58 million. Arvinas had a negative trailing twelve-month return on equity of 59.18% and a negative net margin of 185.09%. Arvinas's revenue for the quarter was up 14.2% on a year-over-year basis. During the same period last year, the company posted ($1.24) earnings per share.

ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ALPS Medical Breakthroughs ETF (SBIO) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (8.85%), Avidity Partners Management LP (4.75%), JPMorgan Chase & Co. (3.61%), Northern Trust Corp (0.87%), Brown Advisory Inc. (0.81%) and Charles Schwab Investment Management Inc. (0.80%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.